M&A Corner
Adamant to acquire 51% ownership of EuroproNET, telecom company15 Jan 2023
Adamant Holding (OTCPK:UCCPF) to acquire 51% interest in EuroproNET Bosnia which holds multiple service telecom licenses and has contracts with... Continue Reading
|
Purple Innovation turns away from Coliseum’s takeover bid15 Jan 2023
Purple Innovation (NASDAQ:PRPL) -2.5% aftermarket on Thursday said it rejected a takeover offer of $4.35 per share from Coliseum Capital... Continue Reading
|
Ra Medical Systems Completes Merger with Catheter Precision15 Jan 2023
MT. OLIVE, N.J. & CARLSBAD, Calif.–(BUSINESS WIRE)– Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces the... Continue Reading
|
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development14 Jan 2023
MAINZ, Germany, and LONDON, United Kingdom, January 10, 2023 –BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd. (“InstaDeep”) today announced that they have entered... Continue Reading
|
Alora Pharmaceuticals Celebrates Acquisition of Monarch Manufacturing Facility14 Jan 2023
ALPHARETTA, Ga., Jan. 10, 2023 /PRNewswire/ — Alora Pharmaceuticals, LLC, is pleased to announce that its wholly owned subsidiary, Sovereign Pharmaceuticals, LLC,... Continue Reading
|
Scipher Medicine Acquires Cross Bridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time14 Jan 2023
WALTHAM, Mass.–(BUSINESS WIRE)– Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data,... Continue Reading
|
Cultivate(MD) Capital Funds Announces Portfolio Company Embody’s Acquisition by Zimmer Biomet Holdings, Inc.14 Jan 2023
GRAND RAPIDS, Mich., Jan. 10, 2023 /PRNewswire/ — cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage healthcare... Continue Reading
|
Amgen Boasts Lucrative Acquisitions, Drug Updates, Burgeoning Biosimilars at JPM14 Jan 2023
Not even a month after purchasing rare disease company Horizon Therapeutics Amgen came to the 41st J.P. Morgan Healthcare Conference in San Francisco to tout... Continue Reading
|
Ipsen to Acquire Albireo for Rare Disease Portfolio14 Jan 2023
French biopharma Ipsen has agreed to acquire Boston-based Albireo Pharma for $42 per share, plus a contingent value right of $10 per share, the two companies... Continue Reading
|
Chiesi Ups Rare Disease Game with $1.48B Amryt Acquisition14 Jan 2023
Italian biopharma Chiesi Farmaceutici SpA announced Sunday it was acquiring rare disease focused AmrytPharma in a deal that could reach up to $1.48 billion... Continue Reading
|